| Description |
Recombinant Human Kremen-2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gly26-Ala364. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q8NCW0 |
| Target Symbol |
Kremen-2 |
| Synonyms |
KRM2; KREMEN2; Kremen-2; Dickkopf receptor 2 |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Gly26-Ala364 |
| Mol. Weight |
The protein has a predicted MW of 37.1 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Activity |
Immobilized Human Kremen-2, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-Kremen-2 Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA. Contact us for detailed testing images. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Kremen2 (Krm2) plays an important role in embryonic development, bone formation, and tumorigenesis as a crucial regulator of classical Wnt/β-catenin signaling pathway. Compared to para-cancerous tissues, Krm2 was significantly up-regulated in gastric cancer tissues and was positively correlated with the pathological grade of gastric cancer patients. Krm2 can be a potent candidate for designing of targeted therapy. |
